The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Sartan-series Drugs Market Research Report 2025
Synopsis
Sartan-series drugs are one of the commonly used clinical antihypertensive drugs, ending with "sartan", such as losartan, valsartan, telmisartan, also known as angiotensin II receptor antagonists or Angiotensin receptor blocker (ARBs). They include irbesartan, valsartan, losartan and candesartan. If the name of a medicine ends in ‘sartan’, it is an ARB.
The global Sartan-series Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Sartan-series Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Sartan-series Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Sartan-series Drugs in Hospital Pharmaty is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Sartan-series Drugs include Novartis, Merck & Co, Sanofi, Pfizer, Bayer, AstraZeneca, Daiichi Sankyo, Takeda, Bristol-Myers Squibb Company, Boehringer Ingelheim, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Sartan-series Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Sartan-series Drugs.
The Sartan-series Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Sartan-series Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Sartan-series Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Merck & Co
Sanofi
Pfizer
Bayer
AstraZeneca
Daiichi Sankyo
Takeda
Bristol-Myers Squibb Company
Boehringer Ingelheim
Abbott
Teva Pharmaceutical
Shenzhen Salubris Pharmaceuticals
Segment by Type
Losartan
Valsartan
Irbesartan
Telmisartan
Olmesartan
Candesartan
Sacubitril/valsartan
Others
Segment by Application
Hospital Pharmaty
Retail Pharmacy
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Sartan-series Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Sartan-series drugs are one of the commonly used clinical antihypertensive drugs, ending with "sartan", such as losartan, valsartan, telmisartan, also known as angiotensin II receptor antagonists or Angiotensin receptor blocker (ARBs). They include irbesartan, valsartan, losartan and candesartan. If the name of a medicine ends in ‘sartan’, it is an ARB.
The global Sartan-series Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Sartan-series Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Sartan-series Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Sartan-series Drugs in Hospital Pharmaty is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Sartan-series Drugs include Novartis, Merck & Co, Sanofi, Pfizer, Bayer, AstraZeneca, Daiichi Sankyo, Takeda, Bristol-Myers Squibb Company, Boehringer Ingelheim, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Sartan-series Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Sartan-series Drugs.
The Sartan-series Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Sartan-series Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Sartan-series Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Merck & Co
Sanofi
Pfizer
Bayer
AstraZeneca
Daiichi Sankyo
Takeda
Bristol-Myers Squibb Company
Boehringer Ingelheim
Abbott
Teva Pharmaceutical
Shenzhen Salubris Pharmaceuticals
Segment by Type
Losartan
Valsartan
Irbesartan
Telmisartan
Olmesartan
Candesartan
Sacubitril/valsartan
Others
Segment by Application
Hospital Pharmaty
Retail Pharmacy
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Sartan-series Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Sartan-series Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Losartan
1.2.3 Valsartan
1.2.4 Irbesartan
1.2.5 Telmisartan
1.2.6 Olmesartan
1.2.7 Candesartan
1.2.8 Sacubitril/valsartan
1.2.9 Others
1.3 Market by Application
1.3.1 Global Sartan-series Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmaty
1.3.3 Retail Pharmacy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Sartan-series Drugs Market Perspective (2019-2030)
2.2 Global Sartan-series Drugs Growth Trends by Region
2.2.1 Global Sartan-series Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Sartan-series Drugs Historic Market Size by Region (2019-2024)
2.2.3 Sartan-series Drugs Forecasted Market Size by Region (2025-2030)
2.3 Sartan-series Drugs Market Dynamics
2.3.1 Sartan-series Drugs Industry Trends
2.3.2 Sartan-series Drugs Market Drivers
2.3.3 Sartan-series Drugs Market Challenges
2.3.4 Sartan-series Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Sartan-series Drugs Players by Revenue
3.1.1 Global Top Sartan-series Drugs Players by Revenue (2019-2024)
3.1.2 Global Sartan-series Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Sartan-series Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Sartan-series Drugs Revenue
3.4 Global Sartan-series Drugs Market Concentration Ratio
3.4.1 Global Sartan-series Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Sartan-series Drugs Revenue in 2023
3.5 Global Key Players of Sartan-series Drugs Head office and Area Served
3.6 Global Key Players of Sartan-series Drugs, Product and Application
3.7 Global Key Players of Sartan-series Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Sartan-series Drugs Breakdown Data by Type
4.1 Global Sartan-series Drugs Historic Market Size by Type (2019-2024)
4.2 Global Sartan-series Drugs Forecasted Market Size by Type (2025-2030)
5 Sartan-series Drugs Breakdown Data by Application
5.1 Global Sartan-series Drugs Historic Market Size by Application (2019-2024)
5.2 Global Sartan-series Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Sartan-series Drugs Market Size (2019-2030)
6.2 North America Sartan-series Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Sartan-series Drugs Market Size by Country (2019-2024)
6.4 North America Sartan-series Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Sartan-series Drugs Market Size (2019-2030)
7.2 Europe Sartan-series Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Sartan-series Drugs Market Size by Country (2019-2024)
7.4 Europe Sartan-series Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Sartan-series Drugs Market Size (2019-2030)
8.2 Asia-Pacific Sartan-series Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Sartan-series Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Sartan-series Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Sartan-series Drugs Market Size (2019-2030)
9.2 Latin America Sartan-series Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Sartan-series Drugs Market Size by Country (2019-2024)
9.4 Latin America Sartan-series Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Sartan-series Drugs Market Size (2019-2030)
10.2 Middle East & Africa Sartan-series Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Sartan-series Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Sartan-series Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Sartan-series Drugs Introduction
11.1.4 Novartis Revenue in Sartan-series Drugs Business (2019-2024)
11.1.5 Novartis Recent Development
11.2 Merck & Co
11.2.1 Merck & Co Company Details
11.2.2 Merck & Co Business Overview
11.2.3 Merck & Co Sartan-series Drugs Introduction
11.2.4 Merck & Co Revenue in Sartan-series Drugs Business (2019-2024)
11.2.5 Merck & Co Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Details
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Sartan-series Drugs Introduction
11.3.4 Sanofi Revenue in Sartan-series Drugs Business (2019-2024)
11.3.5 Sanofi Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Sartan-series Drugs Introduction
11.4.4 Pfizer Revenue in Sartan-series Drugs Business (2019-2024)
11.4.5 Pfizer Recent Development
11.5 Bayer
11.5.1 Bayer Company Details
11.5.2 Bayer Business Overview
11.5.3 Bayer Sartan-series Drugs Introduction
11.5.4 Bayer Revenue in Sartan-series Drugs Business (2019-2024)
11.5.5 Bayer Recent Development
11.6 AstraZeneca
11.6.1 AstraZeneca Company Details
11.6.2 AstraZeneca Business Overview
11.6.3 AstraZeneca Sartan-series Drugs Introduction
11.6.4 AstraZeneca Revenue in Sartan-series Drugs Business (2019-2024)
11.6.5 AstraZeneca Recent Development
11.7 Daiichi Sankyo
11.7.1 Daiichi Sankyo Company Details
11.7.2 Daiichi Sankyo Business Overview
11.7.3 Daiichi Sankyo Sartan-series Drugs Introduction
11.7.4 Daiichi Sankyo Revenue in Sartan-series Drugs Business (2019-2024)
11.7.5 Daiichi Sankyo Recent Development
11.8 Takeda
11.8.1 Takeda Company Details
11.8.2 Takeda Business Overview
11.8.3 Takeda Sartan-series Drugs Introduction
11.8.4 Takeda Revenue in Sartan-series Drugs Business (2019-2024)
11.8.5 Takeda Recent Development
11.9 Bristol-Myers Squibb Company
11.9.1 Bristol-Myers Squibb Company Company Details
11.9.2 Bristol-Myers Squibb Company Business Overview
11.9.3 Bristol-Myers Squibb Company Sartan-series Drugs Introduction
11.9.4 Bristol-Myers Squibb Company Revenue in Sartan-series Drugs Business (2019-2024)
11.9.5 Bristol-Myers Squibb Company Recent Development
11.10 Boehringer Ingelheim
11.10.1 Boehringer Ingelheim Company Details
11.10.2 Boehringer Ingelheim Business Overview
11.10.3 Boehringer Ingelheim Sartan-series Drugs Introduction
11.10.4 Boehringer Ingelheim Revenue in Sartan-series Drugs Business (2019-2024)
11.10.5 Boehringer Ingelheim Recent Development
11.11 Abbott
11.11.1 Abbott Company Details
11.11.2 Abbott Business Overview
11.11.3 Abbott Sartan-series Drugs Introduction
11.11.4 Abbott Revenue in Sartan-series Drugs Business (2019-2024)
11.11.5 Abbott Recent Development
11.12 Teva Pharmaceutical
11.12.1 Teva Pharmaceutical Company Details
11.12.2 Teva Pharmaceutical Business Overview
11.12.3 Teva Pharmaceutical Sartan-series Drugs Introduction
11.12.4 Teva Pharmaceutical Revenue in Sartan-series Drugs Business (2019-2024)
11.12.5 Teva Pharmaceutical Recent Development
11.13 Shenzhen Salubris Pharmaceuticals
11.13.1 Shenzhen Salubris Pharmaceuticals Company Details
11.13.2 Shenzhen Salubris Pharmaceuticals Business Overview
11.13.3 Shenzhen Salubris Pharmaceuticals Sartan-series Drugs Introduction
11.13.4 Shenzhen Salubris Pharmaceuticals Revenue in Sartan-series Drugs Business (2019-2024)
11.13.5 Shenzhen Salubris Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of TablesList of Tables
Table 1. Global Sartan-series Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Losartan
Table 3. Key Players of Valsartan
Table 4. Key Players of Irbesartan
Table 5. Key Players of Telmisartan
Table 6. Key Players of Olmesartan
Table 7. Key Players of Candesartan
Table 8. Key Players of Sacubitril/valsartan
Table 9. Global Sartan-series Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 10. Global Sartan-series Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 11. Global Sartan-series Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 12. Global Sartan-series Drugs Market Share by Region (2019-2024)
Table 13. Global Sartan-series Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 14. Global Sartan-series Drugs Market Share by Region (2025-2030)
Table 15. Sartan-series Drugs Market Trends
Table 16. Sartan-series Drugs Market Drivers
Table 17. Sartan-series Drugs Market Challenges
Table 18. Sartan-series Drugs Market Restraints
Table 19. Global Sartan-series Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 20. Global Sartan-series Drugs Market Share by Players (2019-2024)
Table 21. Global Top Sartan-series Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Sartan-series Drugs as of 2023)
Table 22. Ranking of Global Top Sartan-series Drugs Companies by Revenue (US$ Million) in 2023
Table 23. Global 5 Largest Players Market Share by Sartan-series Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 24. Global Key Players of Sartan-series Drugs, Headquarters and Area Served
Table 25. Global Key Players of Sartan-series Drugs, Product and Application
Table 26. Global Key Players of Sartan-series Drugs, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Sartan-series Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 29. Global Sartan-series Drugs Revenue Market Share by Type (2019-2024)
Table 30. Global Sartan-series Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 31. Global Sartan-series Drugs Revenue Market Share by Type (2025-2030)
Table 32. Global Sartan-series Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 33. Global Sartan-series Drugs Revenue Market Share by Application (2019-2024)
Table 34. Global Sartan-series Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 35. Global Sartan-series Drugs Revenue Market Share by Application (2025-2030)
Table 36. North America Sartan-series Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. North America Sartan-series Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 38. North America Sartan-series Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 39. Europe Sartan-series Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 40. Europe Sartan-series Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 41. Europe Sartan-series Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 42. Asia-Pacific Sartan-series Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Asia-Pacific Sartan-series Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 44. Asia-Pacific Sartan-series Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 45. Latin America Sartan-series Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Latin America Sartan-series Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 47. Latin America Sartan-series Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 48. Middle East & Africa Sartan-series Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 49. Middle East & Africa Sartan-series Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 50. Middle East & Africa Sartan-series Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 51. Novartis Company Details
Table 52. Novartis Business Overview
Table 53. Novartis Sartan-series Drugs Product
Table 54. Novartis Revenue in Sartan-series Drugs Business (2019-2024) & (US$ Million)
Table 55. Novartis Recent Development
Table 56. Merck & Co Company Details
Table 57. Merck & Co Business Overview
Table 58. Merck & Co Sartan-series Drugs Product
Table 59. Merck & Co Revenue in Sartan-series Drugs Business (2019-2024) & (US$ Million)
Table 60. Merck & Co Recent Development
Table 61. Sanofi Company Details
Table 62. Sanofi Business Overview
Table 63. Sanofi Sartan-series Drugs Product
Table 64. Sanofi Revenue in Sartan-series Drugs Business (2019-2024) & (US$ Million)
Table 65. Sanofi Recent Development
Table 66. Pfizer Company Details
Table 67. Pfizer Business Overview
Table 68. Pfizer Sartan-series Drugs Product
Table 69. Pfizer Revenue in Sartan-series Drugs Business (2019-2024) & (US$ Million)
Table 70. Pfizer Recent Development
Table 71. Bayer Company Details
Table 72. Bayer Business Overview
Table 73. Bayer Sartan-series Drugs Product
Table 74. Bayer Revenue in Sartan-series Drugs Business (2019-2024) & (US$ Million)
Table 75. Bayer Recent Development
Table 76. AstraZeneca Company Details
Table 77. AstraZeneca Business Overview
Table 78. AstraZeneca Sartan-series Drugs Product
Table 79. AstraZeneca Revenue in Sartan-series Drugs Business (2019-2024) & (US$ Million)
Table 80. AstraZeneca Recent Development
Table 81. Daiichi Sankyo Company Details
Table 82. Daiichi Sankyo Business Overview
Table 83. Daiichi Sankyo Sartan-series Drugs Product
Table 84. Daiichi Sankyo Revenue in Sartan-series Drugs Business (2019-2024) & (US$ Million)
Table 85. Daiichi Sankyo Recent Development
Table 86. Takeda Company Details
Table 87. Takeda Business Overview
Table 88. Takeda Sartan-series Drugs Product
Table 89. Takeda Revenue in Sartan-series Drugs Business (2019-2024) & (US$ Million)
Table 90. Takeda Recent Development
Table 91. Bristol-Myers Squibb Company Company Details
Table 92. Bristol-Myers Squibb Company Business Overview
Table 93. Bristol-Myers Squibb Company Sartan-series Drugs Product
Table 94. Bristol-Myers Squibb Company Revenue in Sartan-series Drugs Business (2019-2024) & (US$ Million)
Table 95. Bristol-Myers Squibb Company Recent Development
Table 96. Boehringer Ingelheim Company Details
Table 97. Boehringer Ingelheim Business Overview
Table 98. Boehringer Ingelheim Sartan-series Drugs Product
Table 99. Boehringer Ingelheim Revenue in Sartan-series Drugs Business (2019-2024) & (US$ Million)
Table 100. Boehringer Ingelheim Recent Development
Table 101. Abbott Company Details
Table 102. Abbott Business Overview
Table 103. Abbott Sartan-series Drugs Product
Table 104. Abbott Revenue in Sartan-series Drugs Business (2019-2024) & (US$ Million)
Table 105. Abbott Recent Development
Table 106. Teva Pharmaceutical Company Details
Table 107. Teva Pharmaceutical Business Overview
Table 108. Teva Pharmaceutical Sartan-series Drugs Product
Table 109. Teva Pharmaceutical Revenue in Sartan-series Drugs Business (2019-2024) & (US$ Million)
Table 110. Teva Pharmaceutical Recent Development
Table 111. Shenzhen Salubris Pharmaceuticals Company Details
Table 112. Shenzhen Salubris Pharmaceuticals Business Overview
Table 113. Shenzhen Salubris Pharmaceuticals Sartan-series Drugs Product
Table 114. Shenzhen Salubris Pharmaceuticals Revenue in Sartan-series Drugs Business (2019-2024) & (US$ Million)
Table 115. Shenzhen Salubris Pharmaceuticals Recent Development
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
Table 119. Authors List of This Report
List of Figures
Figure 1. Sartan-series Drugs Picture
Figure 2. Global Sartan-series Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Sartan-series Drugs Market Share by Type: 2023 VS 2030
Figure 4. Losartan Features
Figure 5. Valsartan Features
Figure 6. Irbesartan Features
Figure 7. Telmisartan Features
Figure 8. Olmesartan Features
Figure 9. Candesartan Features
Figure 10. Sacubitril/valsartan Features
Figure 11. Others Features
Figure 12. Global Sartan-series Drugs Market Size by Application (2024-2030) & (US$ Million)
Figure 13. Global Sartan-series Drugs Market Share by Application: 2023 VS 2030
Figure 14. Hospital Pharmaty Case Studies
Figure 15. Retail Pharmacy Case Studies
Figure 16. Sartan-series Drugs Report Years Considered
Figure 17. Global Sartan-series Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 18. Global Sartan-series Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 19. Global Sartan-series Drugs Market Share by Region: 2023 VS 2030
Figure 20. Global Sartan-series Drugs Market Share by Players in 2023
Figure 21. Global Top Sartan-series Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Sartan-series Drugs as of 2023)
Figure 22. The Top 10 and 5 Players Market Share by Sartan-series Drugs Revenue in 2023
Figure 23. North America Sartan-series Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. North America Sartan-series Drugs Market Share by Country (2019-2030)
Figure 25. United States Sartan-series Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Canada Sartan-series Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Europe Sartan-series Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Europe Sartan-series Drugs Market Share by Country (2019-2030)
Figure 29. Germany Sartan-series Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. France Sartan-series Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. U.K. Sartan-series Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Italy Sartan-series Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Russia Sartan-series Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Nordic Countries Sartan-series Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Asia-Pacific Sartan-series Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Asia-Pacific Sartan-series Drugs Market Share by Region (2019-2030)
Figure 37. China Sartan-series Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Japan Sartan-series Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. South Korea Sartan-series Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Southeast Asia Sartan-series Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. India Sartan-series Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Australia Sartan-series Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Latin America Sartan-series Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Latin America Sartan-series Drugs Market Share by Country (2019-2030)
Figure 45. Mexico Sartan-series Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Brazil Sartan-series Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Sartan-series Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa Sartan-series Drugs Market Share by Country (2019-2030)
Figure 49. Turkey Sartan-series Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Saudi Arabia Sartan-series Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 51. UAE Sartan-series Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 52. Novartis Revenue Growth Rate in Sartan-series Drugs Business (2019-2024)
Figure 53. Merck & Co Revenue Growth Rate in Sartan-series Drugs Business (2019-2024)
Figure 54. Sanofi Revenue Growth Rate in Sartan-series Drugs Business (2019-2024)
Figure 55. Pfizer Revenue Growth Rate in Sartan-series Drugs Business (2019-2024)
Figure 56. Bayer Revenue Growth Rate in Sartan-series Drugs Business (2019-2024)
Figure 57. AstraZeneca Revenue Growth Rate in Sartan-series Drugs Business (2019-2024)
Figure 58. Daiichi Sankyo Revenue Growth Rate in Sartan-series Drugs Business (2019-2024)
Figure 59. Takeda Revenue Growth Rate in Sartan-series Drugs Business (2019-2024)
Figure 60. Bristol-Myers Squibb Company Revenue Growth Rate in Sartan-series Drugs Business (2019-2024)
Figure 61. Boehringer Ingelheim Revenue Growth Rate in Sartan-series Drugs Business (2019-2024)
Figure 62. Abbott Revenue Growth Rate in Sartan-series Drugs Business (2019-2024)
Figure 63. Teva Pharmaceutical Revenue Growth Rate in Sartan-series Drugs Business (2019-2024)
Figure 64. Shenzhen Salubris Pharmaceuticals Revenue Growth Rate in Sartan-series Drugs Business (2019-2024)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
